Single and Multiple Ascending Dose Study With EP395

Summary

This is a study to asses the safety and tolerability of single and multiple ascending doses of EP395, administered by oral capsules, in healthy subjects with the aim to determine the safe dose range of EP395 for further clinical development

Timeline

Start

2021-04-05

Primary completion

2022-03-22

Completion

2022-03-22

Publications

• Results Singh D, Hanrott K, Breuer O, Bylund J, Schultze B, Norris V. Early clinical pharmacology evaluation of the novel anti-inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions. Br J Clin Pharmacol. 2026 Mar 17. doi: 10.1002/bcp.70509. Online ahead of print.

Drugs

Indications